C
2.13
0.12 (5.97%)
| 前收盘价格 | 2.01 |
| 收盘价格 | 2.09 |
| 成交量 | 2,013,266 |
| 平均成交量 (3个月) | 2,980,476 |
| 市值 | 684,479,808 |
| 股市价格/股市净资产 (P/B) | 5.25 |
| 52周波幅 | |
| 利润日期 | 18 Aug 2025 - 1 Sep 2025 |
| 营业利益率 (TTM) | -635.44% |
| 稀释每股收益 (EPS TTM) | -0.160 |
| 季度收入增长率 (YOY) | -13.50% |
| 流动比率 (MRQ) | 14.55 |
| 营业现金流 (OCF TTM) | -46.84 M |
| 杠杆自由现金流 (LFCF TTM) | -32.27 M |
| 资产报酬率 (ROA TTM) | -36.11% |
| 股东权益报酬率 (ROE TTM) | -53.99% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (AU) | 混合的 | 混合的 |
| Biotechnology (全球的) | 看跌 | 看跌 | |
| 股票 | CLARITY PH FPO [CU6] | - | - |
AIStockmoo 评分
1.0
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | 4.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -0.5 |
| 平均 | 1.00 |
|
Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, based on its platform SAR Technology. The SAR technology is ideally suited for use with copper isotopes, enabling superior imaging and therapeutic characteristics of radiopharmaceutical products and addressing the current manufacturing and logistical limitations in the growth of the radiopharmaceutical sector in oncology. It operates as a single segment, which is Development of Radiopharmaceuticals. Geographically, it operates in Australia and the United States. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 27.52% |
| 机构持股比例 | 19.34% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合